U.S. Oligonucleotide Cdmo Market Size & Outlook, 2025-2033
Related Markets
U.S. oligonucleotide cdmo market highlights
- The U.S. oligonucleotide cdmo market generated a revenue of USD 282.7 million in 2024 and is expected to reach USD 989.8 million by 2033.
- The U.S. market is expected to grow at a CAGR of 15.1% from 2025 to 2033.
- In terms of segment, contract manufacturing was the largest revenue generating service in 2024.
- Contract Development is the most lucrative service segment registering the fastest growth during the forecast period.
Oligonucleotide cdmo market data book summary
| Market revenue in 2024 | USD 282.7 million |
| Market revenue in 2033 | USD 989.8 million |
| Growth rate | 15.1% (CAGR from 2025 to 2033) |
| Largest segment | Contract manufacturing |
| Fastest growing segment | Contract Development |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Contract Manufacturing, Contract Development |
Other key industry trends
- In terms of revenue, U.S. accounted for 31.0% of the global oligonucleotide cdmo market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. oligonucleotide cdmo market is projected to lead the regional market in terms of revenue in 2033.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 989.8 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Oligonucleotide CDMO Market Scope
Oligonucleotide CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| STA Pharmaceutical | View profile | 5001-10000 | Shanghai, Shanghai, China, Asia | https://www.stapharma.com |
| Bachem | View profile | 501-1000 | Bubendorf, Basel-Landschaft, Switzerland, Europe | https://www.bachem.com/ |
| Curia Global, Inc. | View profile | - | - | - |
| Aurigene Pharmaceutical Services Ltd. | View profile | - | - | - |
| Creative Peptides | View profile | 1-10 | New York, New York, United States, North America | http://www.creative-peptides.com/index.html |
| CordenPharma | View profile | 5001-10000 | Plankstadt, Baden-Wurttemberg, Germany, Europe | http://cordenpharma.com |
| SYLENTIS | View profile | 11-50 | Madrid, Madrid, Spain, Europe | http://www.sylentis.com |
| Euroapi SA | View profile | 3326 | 15 rue Traversiere, Paris, France, 75012 | https://www.euroapi.com |
| PolyPeptide Group AG | View profile | 1273 | Neuhofstrasse 24, Baar, Zug, Switzerland, 6340 | https://www.polypeptide.com |
| Merck KGaA | View profile | 62345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | https://www.emdgroup.com |
U.S. oligonucleotide cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oligonucleotide cdmo market will help companies and investors design strategic landscapes.
Contract manufacturing was the largest segment with a revenue share of 72.41% in 2024. Horizon Databook has segmented the U.S. oligonucleotide cdmo market based on contract manufacturing, contract development covering the revenue growth of each sub-segment from 2021 to 2033.
Reasons to subscribe to U.S. oligonucleotide cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. oligonucleotide cdmo market databook
-
Our clientele includes a mix of oligonucleotide cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. oligonucleotide cdmo market , including forecasts for subscribers. This country databook contains high-level insights into U.S. oligonucleotide cdmo market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. oligonucleotide cdmo market size, by service, 2021-2033 (US$M)
U.S. Oligonucleotide CDMO Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
